Today: 17 May 2026
QuantumScape Stock Jumps Toward $8 as Battery Bet Faces Its Big 2026 Test
7 May 2026
2 mins read

QuantumScape Stock Jumps Toward $8 as Battery Bet Faces Its Big 2026 Test

SAN JOSE, May 6, 2026, 15:05 PDT

QuantumScape Corp. was grabbing the spotlight on Wednesday, with shares pushing up near $8 as traders circled back to the battery maker’s ongoing production ramp, customer testing updates, and the company’s persistent cash burn. The stock recently changed hands at $7.95—a 70 cent gain from the prior close—after hitting $7.99 earlier in the session.

This shift is crucial, marking a more intense chapter in QuantumScape’s lengthy commercialization push. The company’s focus now: getting its QSE-5 solid-state lithium-metal battery cells, which rely on solid materials and lithium metal for greater energy density versus standard lithium-ion tech, out of the pilot stage and into the hands of customers for field testing.

QuantumScape, in its first-quarter update, said cells from the Eagle Line pilot facility are now headed for “real-world test conditions.” Customer feedback comes next—critical for product tweaks. The Eagle Line in San Jose, a higher-volume pilot line, is designed to prove whether production can move past lab and small-batch scale.

Normal revenue? Not yet. In its April 24 quarterly filing, QuantumScape reported that planned principal operations remain on hold; as of March 31, the company still hadn’t generated any revenue from its main business activities.

Investors now zero in on operating milestones and the company’s “customer billings” figure—a metric tracking invoices sent out to customers and partners, not to be confused with revenue as defined by U.S. accounting rules. Chief Financial Officer Kevin Hettrich clarified for investors that it’s “not a substitute for revenue under US GAAP.” Investing.com

QuantumScape posted a net loss of $100.8 million for the first quarter, alongside an adjusted EBITDA loss of $63.2 million. That adjusted EBITDA figure strips out interest, taxes, depreciation, amortization, and various other items. The company stuck to its full-year outlook: adjusted EBITDA loss still seen between $250 million and $275 million, with capital expenditures expected in the $40 million to $60 million range.

QuantumScape has finished installing the Eagle Line and kicked off operations, according to Chief Executive Siva Sivaram on the April call. The company, he said, is now “producing initial volumes of QSE-5 cells.” For the second quarter, Sivaram flagged a push to scale up production, aiming to back customer programs across automotive and other sectors. Investing.com

The company kept collaborating with Volkswagen Group’s PowerCo, sent out cells to an automotive joint-development partner for testing, and wrapped up a tech evaluation with yet another top-10 global automaker. “All told, that’s four of the top 10” automakers involved in its auto pipeline, Sivaram said. Investing.com

QuantumScape is pushing to expand its story past electric vehicles. The company has told shareholders there’s interest from AI data centers, defense, aerospace, and government circles. Its partners Murata Manufacturing and Corning are both involved in ceramic separator production. Jamie Huang-Chu, program director of energy materials at Corning, described the company as “optimistic” about helping to deliver “a better battery at a competitive price.”

Time’s tight for solid-state battery players. Solid Power on Tuesday reported it wrapped up site acceptance testing for an SK On pilot cell line, delivered electrolyte to Samsung SDI as part of its joint evaluation project with BMW, and said its own sulfide-electrolyte pilot line remains set for end-2026 commissioning. Both Toyota and Sumitomo Metal Mining have said they’re pushing to make all-solid-state batteries feasible for EVs. Toyota’s aiming for either 2027 or 2028.

Scale is the real challenge here, not just the technical hurdles. Solid-state batteries are supposed to deliver safer, longer-lasting, and quicker-charging options, but as Reuters has noted, major barriers remain: supply constraints on raw materials, tough production processes, and steep costs. If QuantumScape hits snags in field tests, gets lackluster customer reactions, or sees patchy revenue from its partners, it’ll be tough to justify the stock’s recent jump.

On Wednesday, a different Form 144 appeared, disclosing plans for a possible sale of 50,000 common shares related to restricted stock vesting. The document signals intent to resell, but doesn’t confirm any actual share sales.

Stock Market Today

  • Aquestive Therapeutics Reports Strong Q1 Results, Analysts Maintain 2026 Forecasts
    May 16, 2026, 8:17 PM EDT. Aquestive Therapeutics (NASDAQ:AQST) posted strong first-quarter results with revenues of $14 million, surpassing analyst expectations by 33%, and smaller-than-expected losses of $0.07 per share. Despite the upbeat quarter, analysts forecast a 3.6% revenue decline in 2026 to $48.4 million and a 15% decrease in losses to $0.47 per share. The consensus price target remains steady at $8.89, suggesting the stock is trading in line with expectations amid continuing losses. Revenue growth is expected to slow significantly compared to the past five years, lagging behind an 8% annual growth forecast for the wider industry. Investors face mixed views on valuation, with targets ranging from $6.00 to $11.00 per share.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Alaska Air’s $500 Million Debt Sale Shows How Iran War Fuel Shock Is Hitting U.S. Airlines
Previous Story

Alaska Air’s $500 Million Debt Sale Shows How Iran War Fuel Shock Is Hitting U.S. Airlines

Barrick Mining Stock Jumps 7% as Gold Rally Sets Up a Big May 11 Earnings Test
Next Story

Barrick Mining Stock Jumps 7% as Gold Rally Sets Up a Big May 11 Earnings Test

Go toTop